CoChat
Sign Up
Cited by 16Pharmacology and Obesity TreatmentDiabetes Treatment and ManagementDiet and metabolism studies

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index; 122 of the 164 sources its claims cite were checked for support.

Nutrition Strategies for Next‐Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence

Open access
Spreckley, Marie, Ruggiero, Cara F., Brown, Adrian·2026·Obesity Reviews
DOI 10.1111/obr.70079PMC PMC13136787
Open this paper in CoChat — free accountOpen PDF

Abstract

Next‐generation incretin therapies, including semaglutide and tirzepatide, have transformed obesity and Type 2 diabetes management. However, evidence‐based nutritional strategies to support safe and effective use of these agents remain limited. To address this gap, we conducted a systematic scoping review across five databases of studies published between January 2015 and April 2025 to map and appraise clinical trials incorporating nutritional interventions or dietary assessments during semaglutide or tirzepatide therapy in adults with obesity or Type 2 diabetes. Eligible studies included adults receiving semaglutide or tirzepatide with either an active dietary intervention or measured nutrition‐related outcomes. Study quality was assessed using established tools. Twelve studies were included: 10 randomized controlled trials, one non‐randomized comparative study, and one cross‐sectional observational study. Interventions ranged from structured very‐low‐energy or ketogenic diets to general lifestyle counseling and observational dietary assessments. Across studies, energy intake decreased by 24% to 39%, but lean tissue loss accounted for up to 40% of total weight reduction. Only three studies involved nutrition professionals, and systematic assessment of protein or micronutrient intake was rare. One observational study found widespread nutrient inadequacies and limited access to dietetic support. Despite the effectiveness of semaglutide and tirzepatide for weight loss, evidence on optimal dietary strategies is sparse. Early dietitian involvement, high‐protein, nutrient‐dense diets, and routine nutritional monitoring should be prioritized. Robust trials are needed to define best practice for integrating dietary care alongside pharmacotherapy.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

This systematic scoping review found that evidence on nutrition strategies during semaglutide or tirzepatide therapy is sparse and heterogeneous, despite consistent appetite suppression and energy-intake reductions. It concludes that early dietitian involvement, high-protein nutrient-dense diets, and routine nutritional monitoring should be prioritized, but robust trials are needed.

Key findings

  • Twelve studies were included: 10 RCTs, one non-randomized comparative study, and one cross-sectional observational study; energy intake decreased by 24% to 39%, but lean tissue loss accounted for up to 40% of total weight reduction.
  • Only three studies involved nutrition professionals, and systematic assessment of protein or micronutrient intake was rare.
  • In the cross-sectional study of 69 GLP-1 RA users, 72% consumed energy below estimated needs, 54% consumed protein <0.8 g/kg/day, only 10% met ≥1.6 g/kg/day, and 63%–99% were below DRI for multiple micronutrients, with highest deficits for vitamin D (98.6%), potassium (98.6%), and choline (94.2%).
  • In one non-randomized comparative study, tirzepatide plus low-energy ketogenic therapy preserved fat-free mass (−0.5%) and muscle strength (−0.3%) better than low-calorie diet (−4.3% and −4.1%, respectively), despite similar total weight loss.

Methods

  • Systematic scoping review across five databases (PubMed, Embase, Scopus, Web of Science, Google Scholar) for peer-reviewed human studies published January 2015 to April 18, 2025, in adults ≥18 years receiving semaglutide or tirzepatide with an active nutritional intervention or measured nutrition-related outcomes.
  • From 63 records, 43 unique articles were screened independently by two authors; 12 full-text articles met eligibility.
  • Due to heterogeneity, no meta-analysis was performed; findings were narratively synthesized, and risk of bias was assessed with RoB 2 for RCTs and ROBINS-I for non-randomized studies.

Limitations

  • The paper states that only 12 studies addressed both components, most enrolled fewer than 120 participants, and follow-up ranged from 12 to 68 weeks, limiting statistical power and long-term outcome evaluation.
  • The paper states that dietary approaches varied widely, validated dietary assessment tools were inconsistently used, and key nutritional outcomes such as protein intake, micronutrient sufficiency, and gastrointestinal tolerability were seldom measured.
  • The paper states that most studies used DEXA or BIA, which cannot differentiate skeletal muscle from other lean tissue, few involved registered dietitians, and restrictive eligibility excluded high-risk groups such as older adults, sarcopenic obesity, ethnically diverse populations, and those with multimorbidity; most trials also recruited high-income populations, limiting generalizability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1111/obr.70079

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

122 of 164 cited sources checked · 78 supported · 2 flagged · accuracy not yet measured

  • Premisecitation

    In a cross-sectional study of 69 adults using GLP-1 RAs, 72% consumed energy below estimated needs.

    “72% consumed energy below estimated needs”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [20] B. Johnson, M. Milstead, O. Thomas, et al., “ Investigating Nutrient Intake During Use of Glucagon‐Like Peptide‐1 Receptor Agonist: A Cross‐Sectional Study,” Frontiers in Nutrition 12 (2025): 1566498, 10.3389/fnut.2025.1566498. 40352260 PMC12062175 source

      The Discussion (page unavailable) says participants consumed too many calories relative to expert energy recommendations; average intake was 1,748 kcal/day, above the 1,500 kcal/day goal. Its 72% figure refers to participants reporting that they ate more fruits and vegetables since starting a GLP-1RA, not to energy intake below estimated needs. The paper does not report that 72% fell below individual energy needs. (LLM, conf=0.86)

      Checked by a reasoning model — may be wrong.

      Experimental — accuracy not yet measured
  • Findingcitation

    Observational studies embedded within clinical trials and those using other study designs provided important insights into appetite regulation and habitual dietary intake during incretin therapy, despite the absence of structured nutrition interventions or dietitian support.

    “The observational studies embedded within clinical trials and those using other study designs provided important insights into appetite regulation and habitual dietary intake during incretin therapy, despite the absence of structured nutrition interventions or dietitian support [5, 6, 13, 14, 20].”
    Quote in the paperSubstantial claim5 of 5 sources checked
    • cites [5] J. Blundell, G. Finlayson, M. Axelsen, et al., “ Effects of Once‐Weekly Semaglutide on Appetite, Energy Intake, Control of Eating, Food Preference and Body Weight in Subjects With Obesity,” Diabetes, Obesity & Metabolism 19, no. 9 (2017): 1242– 1251, 10.1111/dom.13029. PMC5573908 28266779 source

      Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured
    • cites [6] M. Friedrichsen, A. Breitschaft, S. Tadayon, A. Wizert, and D. Skovgaard, “ The Effect of Semaglutide 2.4 mg Once Weekly on Energy Intake, Appetite, Control of Eating, and Gastric Emptying in Adults With Obesity,” Diabetes, Obesity & Metabolism 23, no. 3 (2021): 754– 762, 10.1111/dom.14261. PMC7898914 33269530 source

      Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured
    • cites [13] C. Gibbons, J. Blundell, S. T. Hoff, K. Dahl, R. Bauer, and T. Bækdal, “ Effects of Oral Semaglutide on Energy Intake, Food Preference, Appetite, Control of Eating, and Body Weight in Subjects With Type 2 Diabetes,” Diabetes, Obesity & Metabolism 23, no. 2 (2020): 581– 588, 10.1111/dom.13960. PMC7839771 33184979 source

      Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured
    • cites [14] T. Heise, J. H. DeVries, S. Urva, et al., “ Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes,” Diabetes Care 46, no. 5 (2023): 998– 1004, 10.2337/dc22-2297. 36857477 PMC10154650 source

      Split into 2 atoms — 0 confirmed, 1 partially supported, 1 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Checked by a reasoning model — may be wrong.

      Experimental — accuracy not yet measured
    • cites [20] B. Johnson, M. Milstead, O. Thomas, et al., “ Investigating Nutrient Intake During Use of Glucagon‐Like Peptide‐1 Receptor Agonist: A Cross‐Sectional Study,” Frontiers in Nutrition 12 (2025): 1566498, 10.3389/fnut.2025.1566498. 40352260 PMC12062175 source

      Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured
  • Premisecitation

    There remains limited practical guidance or statements on dietary support during semaglutide or tirzepatide treatment.

    “Although these agents are now widely prescribed, there remains limited practical guidance or statements on dietary support during treatment [8, 9, 10, 11, 12].”
    Quote in the paperSubstantial claim3 of 5 sources checked
    • cites [8] A. Brown, D. Mellor, J. Makaronidis, E. Shuttlewood, A. D. Miras, and D. J. Pournaras, “ “From Evidence to Practice”–Insights From the Multidisciplinary Team on the Optimal Integration of GLP‐1 Receptor Agonists in Obesity Management Services,” Nutrition Bulletin 49, no. 3 (2024): 257– 263, 10.1111/nbu.12534. 39136338
    • cites [9] British Dietetic Association & British Nutrition Foundation. 2024. Joint Position Statement Regarding GLP‐1/GIP Receptor Agonists in People Living With Obesity and/or Type 2 Diabetes, https://www.nutrition.org.uk/news/joint‐position‐statement‐regarding‐glp‐1gip‐receptor‐agonists.
    • cites [10] D. Mozaffarian, M. Agarwal, M. Aggarwal, et al., “ Nutritional Priorities to Support GLP‐1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society,” American Journal of Clinical Nutrition 122 (2025): 344– 367, 10.1016/j.ajcnut.2025.04.023. 40450457 PMC12612741 source
    • cites [11] J. P. Almandoz, T. A. Wadden, C. Tewksbury, et al., “ Nutritional Considerations With Antiobesity Medications,” Obesity (Silver Spring) 32, no. 9 (2024): 1613– 1631, 10.1002/oby.24067. 38853526 source
    • cites [12] S. Gentinetta, F. Sottotetti, M. Manuelli, and H. Cena, “ Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated With GLP‐1 Receptor Agonist,” Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 17 (2024): 4817– 4824, 10.2147/DMSO.S494919. 39722834 PMC11668918 source

      The Introduction (page unavailable) says that precise recommendations for meal composition and food selection during GLP-1 receptor agonist treatment are lacking; the Results likewise say specific meal-composition guidance remains unavailable. The paper discusses semaglutide, but the passages do not establish the same gap specifically for tirzepatide. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
  • Findingown data

    Three trials had some concerns due to either small sample size or unblinded counseling.

    “Three trials had some concerns due to either small sample size or unblinded counseling [27, 30, 31].”
    Quote in the paperNot a substantial claim1 of 3 sources checked
    • cites [27] H. Bliddal, H. Bays, S. Czernichow, et al., “ Once‐Weekly Semaglutide in Persons With Obesity and Knee Osteoarthritis,” New England Journal of Medicine 391 (2024): 1573– 1583, 10.1056/NEJMoa2304238. 39476339 source
    • cites [30] O. Anyiam, B. Phillips, K. Quinn, et al., “ Metabolic Effects of Very‐Low‐Calorie Diet, Semaglutide, or Combination of the Two, in Individuals With Type 2 Diabetes Mellitus,” Clinical Nutrition 43, no. 8 (2024): 1907– 1913, 10.1016/j.clnu.2024.03.007. 38996661 source
    • cites [31] L. J. Aronne, N. Sattar, D. Horn, et al., “ Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT‐4 Randomized Clinical Trial,” Journal of the American Medical Association 331, no. 1 (2024): 38– 48, 10.1001/jama.2023.21057. 38078870 PMC10714284 source
  • Findingcitation

    Higher protein intake was associated with reduced lean mass loss, even when total weight loss was equivalent.

    “Higher protein intake was associated with reduced lean mass loss, even when total weight loss was equivalent [23].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [23] L. Schiavo, V. Pilone, G. Rossetti, et al., “ Preliminary Evidence Suggests That a 12‐Week Treatment With Tirzepatide Plus Low‐Energy Ketogenic Therapy Is More Effective Than Its Combination With a Low‐Calorie Diet in Preserving Fat‐Free Mass, Muscle Strength, and Resting Metabolic Rate in Patients With Obesity,” Nutrients 17, no. 7 (2025): 1216, 10.3390/nu17071216. 40218974 PMC11990520 source
  • It may state two separate claims as one. 57
  • Probably not a substantial claim. 6
  • The quote only partly states this claim. 9

  • It may state two separate claims as one.

    Premisecitation

    By mimicking endogenous incretin hormones, semaglutide and tirzepatide suppress appetite, increase satiety, and reduce food cravings, resulting in substantial reductions in energy intake.

    “By mimicking endogenous incretin hormones, these agents suppress appetite, increase satiety, and reduce food cravings, resulting in substantial reductions in energy intake [5, 6, 7].”
    Quote in the paperSubstantial claim3 of 3 sources checked
    • cites [5] J. Blundell, G. Finlayson, M. Axelsen, et al., “ Effects of Once‐Weekly Semaglutide on Appetite, Energy Intake, Control of Eating, Food Preference and Body Weight in Subjects With Obesity,” Diabetes, Obesity & Metabolism 19, no. 9 (2017): 1242– 1251, 10.1111/dom.13029. PMC5573908 28266779 source
    • cites [6] M. Friedrichsen, A. Breitschaft, S. Tadayon, A. Wizert, and D. Skovgaard, “ The Effect of Semaglutide 2.4 mg Once Weekly on Energy Intake, Appetite, Control of Eating, and Gastric Emptying in Adults With Obesity,” Diabetes, Obesity & Metabolism 23, no. 3 (2021): 754– 762, 10.1111/dom.14261. PMC7898914 33269530 source

      The Results (Appetite; page not provided) and Discussion report that semaglutide increased satiety, reduced hunger and food cravings, and lowered ad libitum energy intake by 35% versus placebo in adults with obesity. The Introduction identifies semaglutide as a GLP-1 receptor agonist. These passages do not address tirzepatide, so this source supports the claim for semaglutide but not for both agents. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [7] S. Christensen, K. Robinson, S. Thomas, and D. R. Williams, “ Dietary Intake by Patients Taking GLP‐1 and Dual GIP/GLP‐1 Receptor Agonists: A Narrative Review and Discussion of Research Needs,” Obesity Pillars 11 (2024): 100121, 10.1016/j.obpill.2024.100121. 39175746 PMC11340591 source

  • It may state two separate claims as one.

    Premisecitation

    Gastrointestinal side effects, such as nausea, early satiety, and altered taste, are common during incretin therapy and may compromise dietary intake, increasing the risk of deficiencies.

    “Gastrointestinal side effects, such as nausea, early satiety, and altered taste, are common and may compromise dietary intake, increasing the risk of deficiencies [12].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [12] S. Gentinetta, F. Sottotetti, M. Manuelli, and H. Cena, “ Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated With GLP‐1 Receptor Agonist,” Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 17 (2024): 4817– 4824, 10.2147/DMSO.S494919. 39722834 PMC11668918 source

      The Introduction (page not provided) says GLP-1 receptor agonists reduce caloric intake and can cause gastrointestinal symptoms, including nausea. It does not identify altered taste as a side effect or link these symptoms and reduced intake to nutritional deficiencies; its discussion of fullness does not specifically describe early satiety as an adverse effect. (LLM, conf=0.84)

      Experimental — accuracy not yet measured

  • It may state two separate claims as one.

    Premisecitation

    To date, most dietary advice during incretin therapy has focused on calorie reduction, with little emphasis on nutritional adequacy.

    “To date, most dietary advice during incretin therapy has focused on calorie reduction, with little emphasis on nutritional adequacy [1, 9]”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites [1] J. P. H. Wilding, R. L. Batterham, S. Calanna, et al., “ Once‐Weekly Semaglutide in Adults With Overweight or Obesity,” New England Journal of Medicine 384 (2021): 989– 1002, 10.1056/NEJMoa2032183. 33567185 source

      The Procedures section (page not available in our copy) says participants received counseling to follow a diet with a 500-kcal-per-day deficit. It does not assess dietary advice across incretin therapy generally or establish that nutritional adequacy received little emphasis, so the broader claim is unsupported. (LLM, conf=0.82)

      Experimental — accuracy not yet measured
    • cites [9] British Dietetic Association & British Nutrition Foundation. 2024. Joint Position Statement Regarding GLP‐1/GIP Receptor Agonists in People Living With Obesity and/or Type 2 Diabetes, https://www.nutrition.org.uk/news/joint‐position‐statement‐regarding‐glp‐1gip‐receptor‐agonists.

  • It may state two separate claims as one.

    Premisecitation

    Oral semaglutide improved eating control and reduced cravings on CoEQ vs. placebo.

    “Improved eating control, fewer cravings on CoEQ vs. placebo”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [13] C. Gibbons, J. Blundell, S. T. Hoff, K. Dahl, R. Bauer, and T. Bækdal, “ Effects of Oral Semaglutide on Energy Intake, Food Preference, Appetite, Control of Eating, and Body Weight in Subjects With Type 2 Diabetes,” Diabetes, Obesity & Metabolism 23, no. 2 (2020): 581– 588, 10.1111/dom.13960. PMC7839771 33184979 source

  • Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.

    Study design and conductcitation

    Risk of bias was assessed using the Cochrane RoB 2 tool for randomized trials and the ROBINS-I tool for non-randomized studies.

    “Risk of bias was assessed using the Cochrane risk‐of‐bias tool for randomized trials (RoB 2) [24] and the Risk of Bias in Non‐randomized Studies of Interventions (ROBINS‐I) tool [25].”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites [24] J. A. C. Sterne, J. Savović, M. J. Page, et al., “ RoB 2: a revised tool for Assessing Risk of Bias in Randomised Trials,” BMJ (Clinical Research ed.) 366 (2019): l4898, 10.1136/bmj.l4898. 31462531 source
    • cites [25] J. A. C. Sterne, M. A. Hernán, B. C. Reeves, et al., “ ROBINS‐I: A Tool for Assessing Risk of Bias in Non‐Randomised Studies of Interventions,” BMJ 355 (2016): i4919, 10.1136/bmj.i4919. 27733354 PMC5062054 source

  • It may state two separate claims as one.

    Premisecitation

    Oral semaglutide produced greater postprandial satiety, fullness, and lower hunger after fat-rich breakfast (not standard breakfast).

    “Greater postprandial satiety, fullness, and lower hunger after fat‐rich breakfast (not standard breakfast)”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [13] C. Gibbons, J. Blundell, S. T. Hoff, K. Dahl, R. Bauer, and T. Bækdal, “ Effects of Oral Semaglutide on Energy Intake, Food Preference, Appetite, Control of Eating, and Body Weight in Subjects With Type 2 Diabetes,” Diabetes, Obesity & Metabolism 23, no. 2 (2020): 581– 588, 10.1111/dom.13960. PMC7839771 33184979 source

  • It may state two separate claims as one.

    Interpretationreasoning

    Across all structured interventions, the lack of diet-only comparator arms and the inconsistent measurement of protein intake and micronutrient deficiency limited conclusions about the independent contribution of the nutritional component and its role in mitigating nutritional risks.

    “Across all structured interventions [23, 26, 28, 29], the lack of diet‐only comparator arms and the inconsistent measurement of protein intake and micronutrient deficiency limited conclusions about the independent contribution of the nutritional component and its role in mitigating nutritional risks.”
    Quote in the paperSubstantial claim2 of 4 sources checked
    • cites [23] L. Schiavo, V. Pilone, G. Rossetti, et al., “ Preliminary Evidence Suggests That a 12‐Week Treatment With Tirzepatide Plus Low‐Energy Ketogenic Therapy Is More Effective Than Its Combination With a Low‐Calorie Diet in Preserving Fat‐Free Mass, Muscle Strength, and Resting Metabolic Rate in Patients With Obesity,” Nutrients 17, no. 7 (2025): 1216, 10.3390/nu17071216. 40218974 PMC11990520 source

      The Methods (§2.2; page unavailable) state that all participants received tirzepatide with either a ketogenic or low-calorie diet, so this study had no diet-only arm and cannot isolate the effect of diet without the drug. The Methods specify planned protein content and list laboratory tests, including iron (§§2.2–2.3), but do not establish the citing sentence’s broader claim about inconsistent measurement of protein intake and micronutrient deficiency across all four cited interventions. (LLM, conf=0.83)

      Experimental — accuracy not yet measured
    • cites [26] B. M. McGowan, J. M. Bruun, M. Capehorn, et al., “ Efficacy and Safety of Once‐Weekly Semaglutide 2.4 mg Versus Placebo in People With Obesity and Prediabetes (STEP 10): A Randomised, Double‐Blind, Placebo‐Controlled, Multicentre Phase 3 Trial,” Lancet Diabetes and Endocrinology 12, no. 9 (2024): 631– 642, 10.1016/S2213-8587(24)30103-6. 39089293 source
    • cites [28] T. A. Wadden, T. S. Bailey, L. K. Billings, et al., “ Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity,” Journal of the American Medical Association 325, no. 14 (2021): 1403– 1413, 10.1001/jama.2021.2982. 33625476 PMC7905697 source

      Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured
    • cites [29] Y. Mu, X. Bao, F. G. Eliaschewitz, et al., “ Efficacy and Safety of Once‐Weekly Semaglutide 2.4 mg for Weight Management in a Predominantly East Asian Population With Overweight or Obesity (Step 7): A Randomized, Double‐Blind, Placebo‐Controlled, Multicentre Phase 3 Trial,” Lancet Diabetes and Endocrinology 12, no. 3 (2024): 184– 195, 10.1016/S2213-8587(23)30476-X. 38330988

  • It may state two separate claims as one.

    Premisecitation

    Semaglutide and tirzepatide have demonstrated weight-loss efficacy comparable to bariatric surgery, with mean reductions of up to 20.9% in body weight, along with other metabolic benefits, across pivotal trials.

    “Semaglutide and tirzepatide have demonstrated weight‐loss efficacy comparable to bariatric surgery, with mean reductions of up to 20.9% in body weight, along with other metabolic benefits, across pivotal trials [1, 2, 3, 4].”
    Quote in the paperNot a substantial claim1 of 4 sources checked
    • cites [1] J. P. H. Wilding, R. L. Batterham, S. Calanna, et al., “ Once‐Weekly Semaglutide in Adults With Overweight or Obesity,” New England Journal of Medicine 384 (2021): 989– 1002, 10.1056/NEJMoa2032183. 33567185 source

      The Discussion reports 14.9% mean weight loss with semaglutide, improved cardiometabolic risk factors, and that one third of participants lost at least 20%—a reduction approaching that reported after bariatric surgery. This paper does not report a 20.9% mean reduction or results for tirzepatide, so it supports only the semaglutide portion of the sentence. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [2] A. M. Jastreboff, L. J. Aronne, N. N. Ahmad, et al., “ Tirzepatide Once Weekly for the Treatment of Obesity,” New England Journal of Medicine 387 (2022): 205– 216, 10.1056/NEJMoa2206034. 35658024
    • cites [3] A. M. Lincoff, K. Brown‐Frandsen, H. M. Colhoun, et al., “ Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes,” New England Journal of Medicine 389 (2023): 2221– 2232, 10.1056/NEJMoa2311129. 37952131
    • cites [4] A. M. Jastreboff, L. J. Aronne, N. N. Ahmad, et al., “ Tirzepatide Versus Semaglutide Once Weekly in Adults With Obesity Without Diabetes (SURMOUNT‐5),” New England Journal of Medicine 392 (2025): 639– 651, 10.1056/NEJMoa2416394.

  • It may state two separate claims as one.

    Premisecitation

    In a cross-sectional study of 69 adults using GLP-1 RAs, widespread nutrient inadequacies, insufficient protein intake, and minimal access to professional dietary advice were observed.

    “The cross‐sectional study by Johnson et al. (2025) provided additional insights into real‐world dietary practices among incretin therapy users, revealing widespread nutrient inadequacies, insufficient protein intake, and minimal access to professional dietary advice [20].”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [20] B. Johnson, M. Milstead, O. Thomas, et al., “ Investigating Nutrient Intake During Use of Glucagon‐Like Peptide‐1 Receptor Agonist: A Cross‐Sectional Study,” Frontiers in Nutrition 12 (2025): 1566498, 10.3389/fnut.2025.1566498. 40352260 PMC12062175 source

  • It may state two separate claims as one.

    Premisecitation

    Semaglutide 2.4 mg lowered hunger and prospective food consumption and increased satiety and fullness vs. placebo (all p < 0.02).

    “Appetite VAS: lower hunger and prospective food consumption, higher satiety and fullness with semaglutide vs. placebo (all p < 0.02)”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [6] M. Friedrichsen, A. Breitschaft, S. Tadayon, A. Wizert, and D. Skovgaard, “ The Effect of Semaglutide 2.4 mg Once Weekly on Energy Intake, Appetite, Control of Eating, and Gastric Emptying in Adults With Obesity,” Diabetes, Obesity & Metabolism 23, no. 3 (2021): 754– 762, 10.1111/dom.14261. PMC7898914 33269530 source

  • It may state two separate claims as one.

    Premisecitation

    In the same study, 49% did not receive advice on managing side effects; only 20% were referred to an RDN.

    “49% did not receive advice on managing side effects; only 20% referred to an RDN”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [20] B. Johnson, M. Milstead, O. Thomas, et al., “ Investigating Nutrient Intake During Use of Glucagon‐Like Peptide‐1 Receptor Agonist: A Cross‐Sectional Study,” Frontiers in Nutrition 12 (2025): 1566498, 10.3389/fnut.2025.1566498. 40352260 PMC12062175 source

  • The quote only partly states this claim.

    Premisecitation

    Semaglutide 2.4 mg showed no difference in paracetamol Cmax or tmax.

    “No difference in paracetamol Cmax or tmax”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [6] M. Friedrichsen, A. Breitschaft, S. Tadayon, A. Wizert, and D. Skovgaard, “ The Effect of Semaglutide 2.4 mg Once Weekly on Energy Intake, Appetite, Control of Eating, and Gastric Emptying in Adults With Obesity,” Diabetes, Obesity & Metabolism 23, no. 3 (2021): 754– 762, 10.1111/dom.14261. PMC7898914 33269530 source

  • It may state two separate claims as one.

    Premisecitation

    In the same study, 54% consumed protein < 0.8 g/kg/day; 43% met ≥ 1.2 g/kg/day, only 10% ≥ 1.6 g/kg/day.

    “54% consumed protein < 0.8 g/kg/day; 43% met ≥ 1.2 g/kg/day, only 10% ≥ 1.6 g/kg/day”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [20] B. Johnson, M. Milstead, O. Thomas, et al., “ Investigating Nutrient Intake During Use of Glucagon‐Like Peptide‐1 Receptor Agonist: A Cross‐Sectional Study,” Frontiers in Nutrition 12 (2025): 1566498, 10.3389/fnut.2025.1566498. 40352260 PMC12062175 source

      The Discussion reports that 43% consumed at least 1.2 g/kg and 10% at least 1.6 g/kg of protein, calculated using adjusted body weight. It does not report that 54% consumed less than 0.8 g/kg/day; its mention of 0.8 g/kg/day describes the minimum RDA, not the proportion of participants below it. The citing sentence also omits the adjusted-body-weight basis for the reported percentages. (LLM, conf=0.90)

      Experimental — accuracy not yet measured

  • It may state two separate claims as one.

    Premisecitation

    Tirzepatide reduced body weight by −11.2 kg at Week 28 vs. placebo (p < 0.001), vs. −7.0 kg with semaglutide.

    “Tirzepatide reduced body weight by −11.2 kg at Week 28 vs. placebo (p < 0.001), vs. −7.0 kg with semaglutide”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [14] T. Heise, J. H. DeVries, S. Urva, et al., “ Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes,” Diabetes Care 46, no. 5 (2023): 998– 1004, 10.2337/dc22-2297. 36857477 PMC10154650 source

  • It may state two separate claims as one. The quote only partly states this claim.

    Premisecitation

    Semaglutide 1.0 mg showed no differences in palatability ratings or food aversion.

    “No differences in palatability ratings or food aversion”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [5] J. Blundell, G. Finlayson, M. Axelsen, et al., “ Effects of Once‐Weekly Semaglutide on Appetite, Energy Intake, Control of Eating, Food Preference and Body Weight in Subjects With Obesity,” Diabetes, Obesity & Metabolism 19, no. 9 (2017): 1242– 1251, 10.1111/dom.13029. PMC5573908 28266779 source

      The Results (Palatability; page unavailable) say ratings were generally similar between semaglutide and placebo, but report significant differences in lunch taste and evening-meal visual appearance. The paper reports similar nausea ratings, but does not establish that food aversion was unchanged; the Results (Food preference) also report reduced liking for some foods. (LLM, conf=0.88)

      Experimental — accuracy not yet measured

  • It may state two separate claims as one.

    Premisecitation

    In Schiavo et al. (2025), appetite suppression occurred more frequently in the LEKT group (60% vs. 27%) despite similar total weight loss of approximately 10%.

    “Appetite suppression occurred more frequently in the LEKT group, at 60% compared with 27%, despite similar total weight loss of approximately 10% [23].”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [23] L. Schiavo, V. Pilone, G. Rossetti, et al., “ Preliminary Evidence Suggests That a 12‐Week Treatment With Tirzepatide Plus Low‐Energy Ketogenic Therapy Is More Effective Than Its Combination With a Low‐Calorie Diet in Preserving Fat‐Free Mass, Muscle Strength, and Resting Metabolic Rate in Patients With Obesity,” Nutrients 17, no. 7 (2025): 1216, 10.3390/nu17071216. 40218974 PMC11990520 source

  • It may state two separate claims as one. The quote only partly states this claim.

    Premisecitation

    Semaglutide 2.4 mg safety profile was consistent with previous GLP-1 RA trials; GI events were more common but mostly mild.

    “Safety profile consistent with previous GLP‐1 RA trials; GI events more common with semaglutide but mostly mild”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [6] M. Friedrichsen, A. Breitschaft, S. Tadayon, A. Wizert, and D. Skovgaard, “ The Effect of Semaglutide 2.4 mg Once Weekly on Energy Intake, Appetite, Control of Eating, and Gastric Emptying in Adults With Obesity,” Diabetes, Obesity & Metabolism 23, no. 3 (2021): 754– 762, 10.1111/dom.14261. PMC7898914 33269530 source

  • It may state two separate claims as one. The quote only partly states this claim.

    Premisecitation

    Semaglutide 1.0 mg showed no serious AEs; most common were mild/moderate GI symptoms.

    “No serious AEs; most common were mild/moderate GI symptoms”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [5] J. Blundell, G. Finlayson, M. Axelsen, et al., “ Effects of Once‐Weekly Semaglutide on Appetite, Energy Intake, Control of Eating, Food Preference and Body Weight in Subjects With Obesity,” Diabetes, Obesity & Metabolism 19, no. 9 (2017): 1242– 1251, 10.1111/dom.13029. PMC5573908 28266779 source

  • It may state two separate claims as one.

    Premisecitation

    Oral semaglutide reduced body weight by 2.7 kg vs. 0.1 kg with placebo, mainly due to 2.6 kg fat mass loss.

    “Body weight ↓2.7 kg with semaglutide vs. ↓0.1 kg with placebo (mainly due to ↓2.6 kg in fat mass)”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [13] C. Gibbons, J. Blundell, S. T. Hoff, K. Dahl, R. Bauer, and T. Bækdal, “ Effects of Oral Semaglutide on Energy Intake, Food Preference, Appetite, Control of Eating, and Body Weight in Subjects With Type 2 Diabetes,” Diabetes, Obesity & Metabolism 23, no. 2 (2020): 581– 588, 10.1111/dom.13960. PMC7839771 33184979 source

  • It may state two separate claims as one.

    Premisecitation

    Both tirzepatide and semaglutide improved appetite VAS scores vs. placebo, with no significant difference between them.

    “Appetite VAS scores significantly improved with tirzepatide and semaglutide vs. placebo; no significant difference between tirzepatide and semaglutide”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [14] T. Heise, J. H. DeVries, S. Urva, et al., “ Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes,” Diabetes Care 46, no. 5 (2023): 998– 1004, 10.2337/dc22-2297. 36857477 PMC10154650 source

  • It may state two separate claims as one.

    Premisecitation

    Semaglutide 1.0 mg lowered explicit liking and implicit wanting for high-fat, non-sweet foods and increased implicit wanting for low-fat, sweet foods on LFPT.

    “LFPT: lower explicit liking and implicit wanting for high‐fat, non‐sweet foods; higher implicit wanting for low‐fat, sweet foods”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [5] J. Blundell, G. Finlayson, M. Axelsen, et al., “ Effects of Once‐Weekly Semaglutide on Appetite, Energy Intake, Control of Eating, Food Preference and Body Weight in Subjects With Obesity,” Diabetes, Obesity & Metabolism 19, no. 9 (2017): 1242– 1251, 10.1111/dom.13029. PMC5573908 28266779 source

  • It may state two separate claims as one.

    Premisecitation

    Safety outcomes for tirzepatide were consistent with the incretin class; no new safety signals.

    “Safety outcomes reported in separate publication; AEs consistent with incretin class; no new safety signals”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [14] T. Heise, J. H. DeVries, S. Urva, et al., “ Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes,” Diabetes Care 46, no. 5 (2023): 998– 1004, 10.2337/dc22-2297. 36857477 PMC10154650 source

      The Study Design and Participants section states that the study’s safety results were published separately. Our copy does not report that adverse events were consistent with the incretin class or that there were no new safety signals; searches for those terms found no supporting passage. (LLM, conf=0.85)

      Experimental — accuracy not yet measured

  • The quote only partly states this claim.

    Premisecitation

    Semaglutide 2.4 mg significantly increased appetite suppression score (ETD: +13 mm; p = 0.001).

    “Appetite suppression score significantly higher with semaglutide (ETD: +13 mm; p = 0.001)”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [6] M. Friedrichsen, A. Breitschaft, S. Tadayon, A. Wizert, and D. Skovgaard, “ The Effect of Semaglutide 2.4 mg Once Weekly on Energy Intake, Appetite, Control of Eating, and Gastric Emptying in Adults With Obesity,” Diabetes, Obesity & Metabolism 23, no. 3 (2021): 754– 762, 10.1111/dom.14261. PMC7898914 33269530 source

  • It may state two separate claims as one. The quote only partly states this claim.

    Premisecitation

    Semaglutide 1.0 mg reduced hunger, increased satiety, reduced food cravings, and improved control of eating (COEQ).

    “Lower hunger, greater satiety, reduced food cravings, improved control of eating (COEQ)”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [5] J. Blundell, G. Finlayson, M. Axelsen, et al., “ Effects of Once‐Weekly Semaglutide on Appetite, Energy Intake, Control of Eating, Food Preference and Body Weight in Subjects With Obesity,” Diabetes, Obesity & Metabolism 19, no. 9 (2017): 1242– 1251, 10.1111/dom.13029. PMC5573908 28266779 source

  • It may state two separate claims as one. The quote only partly states this claim.

    Premisecitation

    Semaglutide 2.4 mg reduced hunger, improved control of eating, and reduced cravings for savory and dairy foods (p < 0.05) on CoEQ.

    “CoEQ: less hunger, better control of eating, fewer cravings for savory and dairy foods (p < 0.05)”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [6] M. Friedrichsen, A. Breitschaft, S. Tadayon, A. Wizert, and D. Skovgaard, “ The Effect of Semaglutide 2.4 mg Once Weekly on Energy Intake, Appetite, Control of Eating, and Gastric Emptying in Adults With Obesity,” Diabetes, Obesity & Metabolism 23, no. 3 (2021): 754– 762, 10.1111/dom.14261. PMC7898914 33269530 source

  • It may state two separate claims as one.

    Premisecitation

    In Schiavo et al. (2025), the LEKT group achieved significantly greater fat mass reduction (13.4% vs. 10.2%; p = 0.042) and better preservation of fat-free mass (0.5% vs. 4.3%; p = 0.039), muscle strength (0.3% vs. 4.1%; p = 0.046), and resting metabolic rate (1.2% vs. 5.3%; p = 0.019) compared with the LCD group.

    “The LEKT group achieved significantly greater fat mass reduction (13.4% compared with 10.2%; p = 0.042) and better preservation of fat‐free mass (0.5% compared with 4.3%; p = 0.039), muscle strength (0.3% compared with 4.1%; p = 0.046), and resting metabolic rate (1.2% compared with 5.3%; p = 0.019).”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [23] L. Schiavo, V. Pilone, G. Rossetti, et al., “ Preliminary Evidence Suggests That a 12‐Week Treatment With Tirzepatide Plus Low‐Energy Ketogenic Therapy Is More Effective Than Its Combination With a Low‐Calorie Diet in Preserving Fat‐Free Mass, Muscle Strength, and Resting Metabolic Rate in Patients With Obesity,” Nutrients 17, no. 7 (2025): 1216, 10.3390/nu17071216. 40218974 PMC11990520 source

  • It may state two separate claims as one.

    Premisecitation

    In Anyiam et al. (2024), the combination group achieved greater fat mass loss (9.0 kg vs. 4.0 kg), greater reductions in energy intake (1136 kcal/day vs. 480 kcal/day), and a higher percentage of energy from protein (30.0% vs. 18.6%) than the semaglutide-alone group.

    “The combination group achieved greater fat mass loss (9.0 kg compared with 4.0 kg), greater reductions in energy intake (1136 kcal/day compared with 480 kcal/day), and a higher percentage of energy from protein (30.0% compared with 18.6%) than the semaglutide‐alone group.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [30] O. Anyiam, B. Phillips, K. Quinn, et al., “ Metabolic Effects of Very‐Low‐Calorie Diet, Semaglutide, or Combination of the Two, in Individuals With Type 2 Diabetes Mellitus,” Clinical Nutrition 43, no. 8 (2024): 1907– 1913, 10.1016/j.clnu.2024.03.007. 38996661 source

  • It may state two separate claims as one.

    Premisecitation

    Oral semaglutide showed no significant differences in palatability or food aversion.

    “No significant differences in palatability or food aversion (mean VAS > 50 mm for all meals)”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [13] C. Gibbons, J. Blundell, S. T. Hoff, K. Dahl, R. Bauer, and T. Bækdal, “ Effects of Oral Semaglutide on Energy Intake, Food Preference, Appetite, Control of Eating, and Body Weight in Subjects With Type 2 Diabetes,” Diabetes, Obesity & Metabolism 23, no. 2 (2020): 581– 588, 10.1111/dom.13960. PMC7839771 33184979 source

  • It may state two separate claims as one.

    Premisecitation

    Oral semaglutide reduced waist circumference by 2.4 cm vs. 2.0 cm with placebo, but rebound patterns were observed.

    “Waist circumference ↓2.4 cm (semaglutide) vs. ↓2.0 cm (placebo), but rebound patterns observed”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [13] C. Gibbons, J. Blundell, S. T. Hoff, K. Dahl, R. Bauer, and T. Bækdal, “ Effects of Oral Semaglutide on Energy Intake, Food Preference, Appetite, Control of Eating, and Body Weight in Subjects With Type 2 Diabetes,” Diabetes, Obesity & Metabolism 23, no. 2 (2020): 581– 588, 10.1111/dom.13960. PMC7839771 33184979 source

  • The quote only partly states this claim.

    Premisecitation

    Semaglutide 1.0 mg increased appetite suppression score both fasting and postprandially (p = 0.0023).

    “Appetite suppression score higher with semaglutide both fasting and postprandially (p = 0.0023)”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [5] J. Blundell, G. Finlayson, M. Axelsen, et al., “ Effects of Once‐Weekly Semaglutide on Appetite, Energy Intake, Control of Eating, Food Preference and Body Weight in Subjects With Obesity,” Diabetes, Obesity & Metabolism 19, no. 9 (2017): 1242– 1251, 10.1111/dom.13029. PMC5573908 28266779 source

      The Results section (“Appetite, thirst, nausea and well-being”; page unavailable) reports higher appetite suppression scores with semaglutide both fasting and throughout the postprandial period. However, P = .0023 applies to the fasting comparison, not to both periods; the difference in postprandial increases from fasting was not significant. (LLM, conf=0.88)

      Experimental — accuracy not yet measured

  • It may state two separate claims as one.

    Premisecitation

    Semaglutide 1.0 mg reduced lunch intake by ~35% (−1255 kJ; p < 0.0001) and also lowered intake at evening meal and snack box.

    “Lunch intake reduced by ~35% (−1255 kJ; p < 0.0001); also lower intake at evening meal and snack box”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [5] J. Blundell, G. Finlayson, M. Axelsen, et al., “ Effects of Once‐Weekly Semaglutide on Appetite, Energy Intake, Control of Eating, Food Preference and Body Weight in Subjects With Obesity,” Diabetes, Obesity & Metabolism 19, no. 9 (2017): 1242– 1251, 10.1111/dom.13029. PMC5573908 28266779 source

  • It may state two separate claims as one. The quote only partly states this claim.

    Premisecitation

    Oral semaglutide was associated with more adverse events (93 events vs. 51), mostly mild/moderate GI issues.

    “AEs more common with semaglutide (93 events vs. 51); mostly mild/moderate GI issues”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [13] C. Gibbons, J. Blundell, S. T. Hoff, K. Dahl, R. Bauer, and T. Bækdal, “ Effects of Oral Semaglutide on Energy Intake, Food Preference, Appetite, Control of Eating, and Body Weight in Subjects With Type 2 Diabetes,” Diabetes, Obesity & Metabolism 23, no. 2 (2020): 581– 588, 10.1111/dom.13960. PMC7839771 33184979 source

  • It may state two separate claims as one.

    Premisecitation

    In the same study, participants overconsumed % calories from fat (mean 39.9%) and saturated fat (26 g).

    “Participants overconsumed % calories from fat (mean 39.9%) and saturated fat (26 g)”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [20] B. Johnson, M. Milstead, O. Thomas, et al., “ Investigating Nutrient Intake During Use of Glucagon‐Like Peptide‐1 Receptor Agonist: A Cross‐Sectional Study,” Frontiers in Nutrition 12 (2025): 1566498, 10.3389/fnut.2025.1566498. 40352260 PMC12062175 source

  • It may state two separate claims as one.

    Premisecitation

    In the same study, most common side effects were nausea (53.7%), diarrhea (27.8%), and fatigue (30.3%).

    “Most common side effects: nausea (53.7%), diarrhea (27.8%), and fatigue (30.3%)”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [20] B. Johnson, M. Milstead, O. Thomas, et al., “ Investigating Nutrient Intake During Use of Glucagon‐Like Peptide‐1 Receptor Agonist: A Cross‐Sectional Study,” Frontiers in Nutrition 12 (2025): 1566498, 10.3389/fnut.2025.1566498. 40352260 PMC12062175 source

  • It may state two separate claims as one.

    Premisecitation

    Semaglutide 1.0 mg decreased resting metabolic rate (−602 kJ/day; p = 0.0019), but no difference after lean mass adjustment.

    “Resting metabolic rate (RMR) decreased (−602 kJ/day; p = 0.0019), but no difference after lean mass adjustment”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [5] J. Blundell, G. Finlayson, M. Axelsen, et al., “ Effects of Once‐Weekly Semaglutide on Appetite, Energy Intake, Control of Eating, Food Preference and Body Weight in Subjects With Obesity,” Diabetes, Obesity & Metabolism 19, no. 9 (2017): 1242– 1251, 10.1111/dom.13029. PMC5573908 28266779 source

  • It may state two separate claims as one.

    Premisecitation

    In the same study, 63%-99% of participants were below DRI for multiple micronutrients; highest deficits for vitamin D (98.6%), potassium (98.6%), and choline (94.2%).

    “63%–99% of participants below DRI for multiple micronutrients; highest deficits for vitamin D (98.6%), potassium (98.6%), and choline (94.2%)”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [20] B. Johnson, M. Milstead, O. Thomas, et al., “ Investigating Nutrient Intake During Use of Glucagon‐Like Peptide‐1 Receptor Agonist: A Cross‐Sectional Study,” Frontiers in Nutrition 12 (2025): 1566498, 10.3389/fnut.2025.1566498. 40352260 PMC12062175 source

      The Results > Nutrient intake section reports that 98.6% of participants fell below the recommended intake for vitamin D and potassium, and 94.2% for choline; it identifies these as the largest deficits. It does not report the claimed 63% lower end of the range, so that part is not verified by our copy. No page number is available. (LLM, conf=0.86)

      Experimental — accuracy not yet measured

  • It may state two separate claims as one.

    Findingcitation

    There was inconsistent use of validated dietary assessment tools and variation in adherence to recommended macronutrient targets or dietary quality across trials.

    “In addition, there was inconsistent use of validated dietary assessment tools and variation in adherence to recommended macronutrient targets or dietary quality, reducing the comparability and generalizability of findings across trials [13, 14].”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [13] C. Gibbons, J. Blundell, S. T. Hoff, K. Dahl, R. Bauer, and T. Bækdal, “ Effects of Oral Semaglutide on Energy Intake, Food Preference, Appetite, Control of Eating, and Body Weight in Subjects With Type 2 Diabetes,” Diabetes, Obesity & Metabolism 23, no. 2 (2020): 581– 588, 10.1111/dom.13960. PMC7839771 33184979 source

      The Methods (Assessments and endpoints; page unavailable) describe this trial’s appetite questionnaire, weighed meals and test-meal composition. The Discussion (page unavailable) addresses this trial’s limitations, but does not assess inconsistent dietary-assessment tools, adherence to macronutrient targets or dietary quality across trials. Searches for those terms and for cross-trial comparability found no passage supporting the attributed claim. (LLM, conf=0.76)

      Experimental — accuracy not yet measured
    • cites [14] T. Heise, J. H. DeVries, S. Urva, et al., “ Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes,” Diabetes Care 46, no. 5 (2023): 998– 1004, 10.2337/dc22-2297. 36857477 PMC10154650 source

      The Procedures describe appetite ratings and energy intake measured during a buffet-style lunch in one trial. The Conclusions note that a single-lunch measurement may not reflect total energy intake, but do not address inconsistent dietary assessment tools, macronutrient-target adherence, or dietary quality across trials. Searches for those terms and for dietary-intervention limitations found no passage establishing the attributed cross-trial claim. (LLM, conf=0.76)

      Experimental — accuracy not yet measured

  • It may state two separate claims as one.

    Interpretationreasoning

    These constraints limit statistical power and preclude robust evaluation of long-term outcomes, including sustained weight maintenance, micronutrient status, and preservation of lean tissue mass.

    “These constraints limit statistical power and preclude robust evaluation of long‐term outcomes, including sustained weight maintenance, micronutrient status, and preservation of lean tissue mass [5, 18, 28].”
    Quote in the paperSubstantial claim2 of 3 sources checked
    • cites [5] J. Blundell, G. Finlayson, M. Axelsen, et al., “ Effects of Once‐Weekly Semaglutide on Appetite, Energy Intake, Control of Eating, Food Preference and Body Weight in Subjects With Obesity,” Diabetes, Obesity & Metabolism 19, no. 9 (2017): 1242– 1251, 10.1111/dom.13029. PMC5573908 28266779 source

      Materials and Methods (Statistical analysis; Assessments, pages unavailable) describe a 30-subject study powered for its energy-intake endpoint and 12-week treatment periods, supporting the concern that it cannot establish long-term outcomes. The Results (Body weight and body composition, page unavailable) assess lean mass only after 12 weeks. The paper does not evaluate sustained weight maintenance or micronutrient status, and it does not say statistical power was limited for its primary endpoint. (LLM, conf=0.85)

      Experimental — accuracy not yet measured
    • cites [18] J. P. H. Wilding, R. L. Batterham, S. Calanna, et al., “ Once‐Weekly Semaglutide in Adults With Overweight or Obesity as an Adjunct to Various Dietary Interventions: The STEP 1, 2 and 3 Trial Designs,” Lancet 396, no. 10263 (2021): 1997– 2009, 10.1016/S0140-6736(20)32332-1.
    • cites [28] T. A. Wadden, T. S. Bailey, L. K. Billings, et al., “ Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity,” Journal of the American Medical Association 325, no. 14 (2021): 1403– 1413, 10.1001/jama.2021.2982. 33625476 PMC7905697 source

      The Limitations section (page not provided) says the 68-week trial could not determine whether participants would sustain their weight loss with continued treatment. It does not address micronutrient status or preservation of lean tissue mass. Nor does its Statistical Analysis section support a general claim of limited statistical power: it reports greater than 99% power for the co-primary end points. (LLM, conf=0.87)

      Experimental — accuracy not yet measured

  • It may state two separate claims as one.

    Premisecitation

    Nutritional deficiencies and cholelithiasis are known risks during rapid weight loss.

    “Key variables such as dietary protein intake, micronutrient sufficiency, and gastrointestinal tolerability were seldom measured, despite known risks of nutritional deficiencies and cholelithiasis during rapid weight loss [38, 40, 41, 42, 43].”
    Quote in the paperSubstantial claim1 of 5 sources checked
    • cites [38] J. I. Mechanick, C. M. Apovian, S. Brethauer, et al., “ Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures ‐ 2019 Update,” Surgery for Obesity and Related Diseases 16, no. 2 (2020): 175– 247, 10.1016/j.soard.2019.09.021. 31917200
    • cites [40] A. Damms‐Machado, G. Weser, and S. C. Bischoff, “ Micronutrient Deficiency in Obese Subjects Undergoing Low Calorie Diet,” Nutrition Journal 11 (2012): 34, 10.1186/1475-2891-11-34. 22657586 PMC3404899 source

      The Discussion reports that more subjects had micronutrient deficiencies after three months of a low-calorie formula diet, supporting the nutritional-deficiency risk during weight loss. The paper does not address cholelithiasis; a search for cholelithiasis, gallstones, and gallbladder found no supporting passage in our copy. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [41] M. M. Smits, L. Tonneijck, M. H. A. Muskiet, M. H. H. Kramer, D. L. Cahen, and D. H. van Raalte, “ Gastrointestinal Actions of GLP‐1‐Based Therapies: Glycaemic Control Beyond the Pancreas,” Diabetes Care 39, no. 6 (2016): 1071– 1079, 10.2337/dc15-2307. 26500045
    • cites [42] K. A. Gudzune, M. M. Huizinga, H. Y. Chang, V. Asamoah, M. Gadgil, and J. Clark, “ Screening and Diagnosis of Micronutrient Deficiencies Before and After Bariatric Surgery,” Obesity Surgery 23, no. 10 (2013): 1581– 1589, 10.1007/s11695-013-1016-2. 23515975 PMC3740071
    • cites [43] Y. Dai, B. Luo, and W. Li, “ Incidence and Risk Factors for Cholelithiasis After Bariatric Surgery: A Systematic Review and Meta‐Analysis,” Lipids in Health and Disease 22, no. 1 (2023): 1– 14, 10.1186/s12944-023-02050-3. 36641461 PMC9840335

  • It may state two separate claims as one.

    Findingreasoning

    Across the included trials, validated measures of dietary quality were not used, representing a key evidence gap.

    “Across trials, validated measures of dietary quality were not used, representing a key evidence gap.”
    Quote in the paperSubstantial claim

  • It may state two separate claims as one.

    Findingown data

    Sample sizes ranged from 15 to 670 participants, with intervention durations ranging from 12 to 68 weeks in the interventional studies.

    “Sample sizes ranged from 15 to 670 participants, with intervention durations ranging from 12 to 68 weeks in the interventional studies.”
    Quote in the paperNot a substantial claim

  • It may state two separate claims as one.

    Findingown data

    Twelve studies were included in the review: 10 randomized controlled trials, one non-randomized comparative study, and one cross-sectional observational study.

    “Twelve studies were included: 10 randomized controlled trials, one non‐randomized comparative study, and one cross‐sectional observational study.”
    • Also stated in: § Search Criteria · plain
      “Twelve full‐text articles were included: 10 randomized controlled trials (RCTs), one prospective non‐randomized comparative study, and one cross‐sectional observational study.”
    • Also stated in: § Results · plain
      “Twelve full‐text articles met the inclusion criteria. These comprised 10 RCTs, one prospective non‐randomized comparative study [23], and one cross‐sectional observational study [20].”
    Quote in the paperSubstantial claim

  • It may state two separate claims as one.

    Findingcitation

    Most included studies included adults with obesity or T2D, although two studies also included people with prediabetes or knee osteoarthritis.

    “Most studies included adults with obesity or T2D, although two studies also included people with prediabetes [26] or knee osteoarthritis [27].”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [26] B. M. McGowan, J. M. Bruun, M. Capehorn, et al., “ Efficacy and Safety of Once‐Weekly Semaglutide 2.4 mg Versus Placebo in People With Obesity and Prediabetes (STEP 10): A Randomised, Double‐Blind, Placebo‐Controlled, Multicentre Phase 3 Trial,” Lancet Diabetes and Endocrinology 12, no. 9 (2024): 631– 642, 10.1016/S2213-8587(24)30103-6. 39089293 source
    • cites [27] H. Bliddal, H. Bays, S. Czernichow, et al., “ Once‐Weekly Semaglutide in Persons With Obesity and Knee Osteoarthritis,” New England Journal of Medicine 391 (2024): 1573– 1583, 10.1056/NEJMoa2304238. 39476339 source

  • It may state two separate claims as one.

    Findingnone given

    Across the 12 included studies, semaglutide and tirzepatide were consistently associated with appetite suppression, reductions in ad libitum energy intake, and substantial fat mass loss.

    “Across the 12 included studies, these medications were consistently associated with appetite suppression, reductions in ad libitum energy intake, and substantial fat mass loss.”
    Quote in the paperSubstantial claim

  • It may state two separate claims as one.

    Findingnone given

    Trials incorporating lifestyle counseling contributed large sample sizes and offered pragmatic relevance to real-world clinical practice.

    “The trials that incorporated lifestyle counseling contributed large sample sizes and offered pragmatic relevance to real‐world clinical practice.”
    Quote in the paperNot a substantial claim

  • It may state two separate claims as one.

    Findingown data

    No trial incorporating lifestyle counseling collected comprehensive dietary intake data or assessed nutrition-related complications such as vitamin or mineral deficiencies.

    “Involvement of registered dietitians was minimal or absent, and no trial collected comprehensive dietary intake data or assessed nutrition‐related complications such as vitamin or mineral deficiencies.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim.

    Findingnone given

    At present, comprehensive nutritional and behavioral care is missing from the standard of care for incretin therapies.

    “At present, this remains missing from the standard of care and concerns continue to mount regarding clinical services prescribing incretin therapies without comprehensive wrap‐around care, which should be mandatory.”
    Quote in the paperSubstantial claim

  • It may state two separate claims as one.

    Findingown data

    The literature combining incretin therapies with structured nutrition interventions remains limited and methodologically diverse.

    “Despite the increasing use of incretin therapies in obesity and T2D management, the literature combining these agents with structured nutrition interventions remains limited and methodologically diverse.”
    Quote in the paperSubstantial claim

  • It may state two separate claims as one.

    Findingnone given

    Most included trials recruited high-income populations, limiting generalizability.

    “Notably, most included trials recruited high‐income populations, limiting generalizability.”
    Quote in the paperSubstantial claim

  • It may state two separate claims as one.

    Findingnone given

    Current trials consistently demonstrate that semaglutide and tirzepatide lead to substantial appetite suppression and fat mass reduction.

    “Although current trials consistently demonstrate that semaglutide and tirzepatide lead to substantial appetite suppression and fat mass reduction, the wide variation in dietary protocols, lack of standardized nutrition assessments, and limited early involvement of registered dietitians reduce the applicability of findings to clinical practice.”
    Quote in the paperNot a substantial claim

  • It may state two separate claims as one.

    Findingown data

    The majority of trials prioritized weight and glycaemic endpoints such as HbA1c and insulin resistance (HOMA-IR), while broader nutritional outcomes were frequently underreported.

    “The majority of trials prioritized weight and glycaemic endpoints such as glycated hemoglobin (HbA1c) and insulin resistance (i.e., HOMA‐IR), while broader nutritional outcomes were frequently underreported.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.

    Study design and conductnone given

    Two authors independently applied domain-level risk-of-bias judgments, with discrepancies resolved by consensus.

    “Two authors independently applied domain‐level judgments, with discrepancies resolved by consensus.”
    Quote in the paperNot a substantial claim

  • It may state two separate claims as one.

    Premisecitation

    In the SURMOUNT-4 trial, participants who switched to placebo regained weight (mean increase of 14% between weeks 36 and 88), while those who continued tirzepatide lost an additional 5.5% of body weight.

    “During the maintenance phase, those who switched to placebo regained weight (mean increase of 14% between weeks 36 and 88), while those who continued tirzepatide lost an additional 5.5% of body weight.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [31] L. J. Aronne, N. Sattar, D. Horn, et al., “ Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT‐4 Randomized Clinical Trial,” Journal of the American Medical Association 331, no. 1 (2024): 38– 48, 10.1001/jama.2023.21057. 38078870 PMC10714284 source

  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Study design and conductown data

    Records were screened independently by two authors (M.S. and C.F.R.).

    “After removing duplicates, 43 unique articles were screened independently by two authors (M.S. and C.F.R.).”
    Quote in the paperNot a substantial claim

  • It may state two separate claims as one.

    Interpretationreasoning

    The evidence suggests that macronutrient composition and structured delivery of the dietary interventions may influence outcomes beyond weight loss alone, including the preservation of metabolic rate and muscle mass and possibly satiety and adherence.

    “Nevertheless, the evidence suggests that macronutrient composition and structured delivery of the dietary interventions may influence outcomes beyond weight loss alone, including the preservation of metabolic rate and muscle mass and possibly satiety and adherence.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Study design and conductnone given

    Data extraction was conducted independently by the first two authors (M.S. and C.F.R.) using a standardized template.

    “Data extraction was conducted independently by the first two authors (M.S. and C.F.R.) using a standardized template.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim.

    Study design and conductnone given

    A systematic literature search was conducted on 26 April 2025 across five databases (PubMed, Embase, Scopus, Web of Science, and Google Scholar) to identify peer-reviewed studies published between January 2015 and April 18, 2025.

    “A systematic literature search was conducted on 26 April 2025 across five databases (PubMed, Embase, Scopus, Web of Science, and Google Scholar) to identify peer‐reviewed studies published between January 2015 and April 18, 2025.”
    Quote in the paperSubstantial claim

  • It may state two separate claims as one.

    Premisecitation

    In the SURMOUNT-4 trial, serious adverse events were similar across groups; 1.8% discontinued tirzepatide due to AEs.

    “Serious adverse events similar across groups; 1.8% discontinued tirzepatide due to AEs”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [31] L. J. Aronne, N. Sattar, D. Horn, et al., “ Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT‐4 Randomized Clinical Trial,” Journal of the American Medical Association 331, no. 1 (2024): 38– 48, 10.1001/jama.2023.21057. 38078870 PMC10714284 source

  • It may state two separate claims as one.

    Premisecitation

    The design and delivery of dietary components in clinical trials of incretin therapies have been highly variable, with inconsistent macronutrient goals and limited professional oversight.

    “the design and delivery of dietary components in clinical trials have been highly variable, with inconsistent macronutrient goals and limited professional oversight [18, 19].”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [18] J. P. H. Wilding, R. L. Batterham, S. Calanna, et al., “ Once‐Weekly Semaglutide in Adults With Overweight or Obesity as an Adjunct to Various Dietary Interventions: The STEP 1, 2 and 3 Trial Designs,” Lancet 396, no. 10263 (2021): 1997– 2009, 10.1016/S0140-6736(20)32332-1.
    • cites [19] X. Pi‐Sunyer, A. Astrup, K. Fujioka, et al., “ Liraglutide 3.0 mg for Weight Management: Rationale and Design of the SCALE Obesity and Prediabetes Nutritional Guidance and Counselling Protocol,” Obesity (Silver Spring, Md.) 23, no. 3 (2015): 45– 55, 10.1002/oby.21093.

  • It may state two separate claims as one.

    Premisecitation

    In McGowan et al. (2024), weight loss with semaglutide was greater than with placebo (13.9% vs. 2.7%), and 81% of participants reverted to normoglycemia compared with 14% in the placebo group.

    “Weight loss with semaglutide was greater than with placebo (13.9% compared with 2.7%), and 81% of participants reverted to normoglycemia compared with 14% in the placebo group”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [26] B. M. McGowan, J. M. Bruun, M. Capehorn, et al., “ Efficacy and Safety of Once‐Weekly Semaglutide 2.4 mg Versus Placebo in People With Obesity and Prediabetes (STEP 10): A Randomised, Double‐Blind, Placebo‐Controlled, Multicentre Phase 3 Trial,” Lancet Diabetes and Endocrinology 12, no. 9 (2024): 631– 642, 10.1016/S2213-8587(24)30103-6. 39089293 source

  • It may state two separate claims as one.

    Premisecitation

    In Mu et al. (2024), weight loss was significantly greater with semaglutide (12.1% vs. 3.6%; p < 0.0001), and 85% achieved at least 5% weight loss.

    “weight loss was significantly greater with semaglutide (12.1% compared with 3.6%; p < 0.0001), and 85% achieved at least 5% weight loss”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [29] Y. Mu, X. Bao, F. G. Eliaschewitz, et al., “ Efficacy and Safety of Once‐Weekly Semaglutide 2.4 mg for Weight Management in a Predominantly East Asian Population With Overweight or Obesity (Step 7): A Randomized, Double‐Blind, Placebo‐Controlled, Multicentre Phase 3 Trial,” Lancet Diabetes and Endocrinology 12, no. 3 (2024): 184– 195, 10.1016/S2213-8587(23)30476-X. 38330988

  • It may state two separate claims as one.

    Interpretationreasoning

    The limited involvement of registered dietitians or qualified professionals reduced the reliability of reported dietary adherence and intake data and raised concern about dietary adequacy while on these therapies.

    “Few studies involved registered dietitians or other qualified professionals in the design or delivery of the nutrition intervention, further reducing the reliability of reported dietary adherence and intake data and presenting concern about dietary adequacy while on these therapies.”
    Quote in the paperSubstantial claim

  • It may state two separate claims as one.

    Interpretationreasoning

    Wide variation in dietary protocols, lack of standardized nutrition assessments, and limited early involvement of registered dietitians reduce the applicability of findings to clinical practice.

    “Although current trials consistently demonstrate that semaglutide and tirzepatide lead to substantial appetite suppression and fat mass reduction, the wide variation in dietary protocols, lack of standardized nutrition assessments, and limited early involvement of registered dietitians reduce the applicability of findings to clinical practice.”
    Quote in the paperSubstantial claim

  • It may state two separate claims as one.

    Interpretationcitation

    Food insecurity may lead to poorer dietary quality, amplify nutritional risks, and highlight the importance of accessible, dietitian-led care.

    “This may lead to poorer dietary quality [49], amplify nutritional risks, and highlight the importance of accessible, dietitian‐led care.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [49] R. A. Stone, P. Christiansen, A. M. Johnstone, A. Brown, F. Douglas, and C. A. Hardman, “ Understanding the Barriers to Purchasing Healthier, More Environmentally Sustainable Food for People Living With Obesity and Varying Experiences of Food Insecurity in the UK,” Food Policy 131 (2025): 102798, 10.1016/j.foodpol.2025.102798.
64 of 64

  • The paper relies on this without support.

    Liraglutide has slower and more modest effects on weight loss compared with semaglutide and tirzepatide.

    “Liraglutide was excluded as this is a once‐daily injection and, due to its slower and more modest effects on weight loss compared with semaglutide and tirzepatide, was outside the scope of this review.”

  • The paper relies on this without support.

    Routine dietitian-led support during incretin therapy improves nutritional outcomes.

    “underscore the need for routine, dietitian‐led support during incretin therapy, ideally as part of holistic multidisciplinary care.”

  • The paper relies on this without support.

    The nutrient inadequacies observed in cross-sectional studies of GLP-1 RA users are attributable to the incretin therapy rather than to pre-existing dietary habits or other factors.

    “revealing widespread nutrient inadequacies, insufficient protein intake, and minimal access to professional dietary advice [20].”

  • The paper relies on this without support.

    Nutritional guidelines and care models developed for bariatric surgery patients are applicable to patients receiving incretin therapies for obesity.

    “which aligns with guidelines for surgical weight loss patients and nutritional priorities to support GLP‐1 therapy for obesity [10, 34].”
    “informed by existing bariatric care models [38].”

  • The paper relies on this without support.

    Access to more comprehensive body composition measures such as MRI is limited in clinical practice.

    “However, due to limitations of access to more comprehensive body composition measures in clinical practice, the use of BIA offers a practical solution to understanding the impact of incretin therapies on, as a minimum, fat free mass.”
5 of 5

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • A randomized trial did monitor dietary intake

    Major

    The claim that no randomized trial monitored habitual nutrient intake conflicts with the description of Anyiam et al., a randomized trial that collected four-day diet diaries at baseline and Week 6.

  • Conflicting tirzepatide dose for Schiavo et al.

    Major

    The narrative says tirzepatide was escalated to 10 mg and then 15 mg, whereas Table 2 says participants received 2.5 mg for four weeks followed by 5 mg for eight weeks.

  • VLCD described as food-based despite meal replacements

    Minor

    The narrative calls Anyiam et al.'s VLCD food-based, while Table 2 describes it as a total meal-replacement diet supplemented with fruits and vegetables.

3 of 3

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 11

  1. 10.1056/nejmoa2206034 · DOI
  2. 10.1056/nejmoa2311129 · DOI
  3. 10.1016/s2213‐8587(24)30103‐6 · DOI
  4. 10.1056/nejmoa2304238 · DOI
  5. 10.1001/jama.2021.2982 · DOI
  6. 10.1016/s2213‐8587(23)30476‐x · DOI
  7. 10.1001/jama.2023.21057 · DOI
  8. 10.2337/dc15‐2307 · DOI
  9. 10.1007/s11695‐013‐1016‐2 · DOI
  10. 10.1186/s12944‐023‐02050‐3 · DOI
  11. Marmot M., 2010, Fair Society, Healthy Lives: The Marmot Review

Cited by

Sorted by citations

Related

Metadata

Authors
Spreckley, M., Ruggiero, C. F., & Brown, A.
Affiliations
  • University of Cambridge (GB)
  • University College Hospital (GB)
Corresponding author
Brown, Adrian
ORCID
Venue
Obesity Reviews
Publisher
Wiley
Published
2026-01-07
Volume
27
Issue
6
Pages
e70079-e70079
ISSN
  • 1467-7881 (ISSN-L)
  • 1467-789X
DOI
10.1111/obr.70079
PMC
PMC13136787
OpenAlex
W7118845250
Semantic Scholar
845536d26e4cdacc04a20e3e3153e7af8dbcd518
Cited by
16
References
34
Citations by year
2026: 16
FWCI
11.84
Type
journal article
Language
en
Open access
Licence
Locations
  • Obesity Reviews (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
Funders
National Institute for Health and Care Research (303041)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Physiology (medical) › Diet and metabolism studies
Keywords
semaglutide, tirzepatide, incretin-based therapy, obesity, type 2 diabetes, dietary intervention, very low calorie diet, ketogenic diet, weight loss, lean tissue loss, protein intake, micronutrient inadequacy, dietitian involvement, nutritional monitoring, lifestyle counseling
MeSH terms
Tirzepatide, Semaglutide, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Obesity, Weight Loss, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review